EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) Shares Drop on Q3 Earnings and Revenue Miss EyePoint Pharmaceuticals stock falls after Q3 2025 earnings miss estimates. Despite the financial setback, its key DURAVYU trials for wet AMD are fully enrolled and on track for 2026 data.
EyePoint Pharmaceuticals Raises Capital As It Advances Lead Product To Pivotal Study EyePoint Pharmaceuticals outlines Phase 3 trials for Duravyu in diabetic macular edema, backed by $150 million in new funding.
EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) Q2 2025 Earnings Miss Estimates as Shares Drop 4.5% Pre-Market EyePoint Pharmaceuticals (EYPT) Q2 2025 earnings miss estimates with $5.33M revenue and -$0.85 EPS, sparking a 4.5% pre-market drop. Clinical progress in DURAVYU Phase 3 trial offers hope amid financial setbacks.
Breakout Momentum Plays You May Not Know About Momentum investing is all about timing—these three under-the-radar stocks have begun to rise by still seem to have room for further growth.
These stocks are moving in today's pre-market session Wondering what's happening in Wednesday's pre-market session? Find an overview in this article.
EyePoint's Investigational Drug Shows Early And Sustained Improvement Than Regeneron's Eylea For Diabetes-Associated Vision Loss EyePoint Pharmaceuticals' shares rise as interim Phase 2 VERONA trial data shows Duravyu improves visual acuity and anatomy in diabetic macular edema patients.
